QUARTERLY REVIEW中文

Alnylam Q3 2026: shares fall 25%; US demand adds less revenue than in Q2

By · AI-assisted, human-reviewed and edited · · Updated · 12 sources · Fact-checked · 6 min read

Did the story change? Mixed

Partly: Alnylam's sales kept growing, but it said higher demand for its TTR drugs Amvuttra and Onpattro added less US revenue than in Q2, and its cost of goods sold rose. The company reiterated its full-year guidance, though its CFO said TTR sales would land at the low end of the $4.2–4.5 billion range, while moving two early clinical updates to February 2027, and reported net income included a large non-cash tax benefit. The stock closed down 25%.

Prices are official Nasdaq closes for Oct 28 and Oct 29, 2026.

Snapshot at the Oct 29, 2026 close

Enterprise value
$20.7B†
Price/sales
4.6×
P/E
8.8×*
Price/FCF
28.9×
Revenue growth
+56%
Net cash
$2.6B†

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $174.00 (official close, Nasdaq); 133.9 million shares (10-Q cover, Oct 23, 2026). n/m = not meaningful (e.g. negative earnings). * Trailing P/E includes a $1.9B one-off tax benefit (release of a valuation allowance; company-reported, rounded). † Debt excludes ~$1.735B of royalty and development-funding liabilities to Blackstone, which the company reports separately. Corrected Nov 3, 2026: the one-off tax benefit is now the $1.95B valuation-allowance release (10-Q, Q3 2026), not the total 12-month tax benefit ($1.87B); the royalty and funding liabilities are owed to Blackstone only. Values and multiples unchanged.

Alnylam’s third-quarter release shows its main drug still growing and its full-year guidance ranges unchanged, with TTR sales expected at the low end, but a smaller quarterly increase in US demand-related sales. Amvuttra, a quarterly injection for transthyretin (TTR) amyloidosis, a disease in which a misfolded protein damages the heart and nerves, brought in $1.13 billion, about 78% of Alnylam’s $1.46 billion of total revenue. Alnylam reiterated every line of its 2026 guidance, three months after cutting its TTR sales outlook in July, but CFO Jeff Poulton said TTR sales would land at the low end of the range. The stock fell sharply after the release.

Why the stock fell

Alnylam shares closed at $174.00 on Oct 29, down 25.1% from the Oct 28 close of $232.40, according to Nasdaq’s quote page (4:00 p.m. ET close; Nasdaq). Our read: the quarter raises questions about the pace of sales growth, product costs and pipeline timing.

  • Alnylam attributed less additional US TTR revenue to demand than in Q2: $81 million, against $129 million a quarter earlier. Part of the rest of the increase came from inventory and price adjustments.
  • Cost of goods sold reached 28% of product sales, versus 25.4% in Q2 and 23.2% a year earlier. Alnylam attributed the year-on-year rise mainly to the higher blended royalty rate it pays Sanofi as Amvuttra sales grow.
  • Alnylam moved two early clinical-data updates, for ALN-6400 and ALN-2232, from the second half of 2026 to February 2027.
  • Alnylam reiterated its TTR sales guidance, which it had cut in July, but its CFO said TTR sales would land at the low end of the range.

On Oct 29, Stifel lowered its rating to Hold from Buy with a $225 target, according to MarketBeat. Earlier target changes came before the results: UBS kept a Buy rating and cut its target to $354 from $550 on Oct 15, according to an ad-hoc-news report, and Jefferies cut its target to $250 from $260, keeping a Hold rating, Investing.com reported on Oct 16.

Did the story change?

The table compares the second and third quarters and what management said in July and October.

Driver Q2 → Q3 2026 Management: July → October Signal
US Amvuttra sales $809M → $909M 2026 TTR sales guidance $4.2–4.5B (cut Jul 30) → $4.2–4.5B reiterated; CFO expects the low end Better
Additional US TTR revenue from higher demand, vs prior quarter +$129M → +$81M; Q3 also gained a $17M inventory benefit and about $10M of favourable price adjustments Q2: growth offset by inventory and a small price cut → Q3: inventory and price added to growth Watch
Amvuttra outside the US $203M → $222M Alnylam attributed international TTR growth to heart-disease launches in Japan, Germany and Italy and the timing of partner orders Better
Cost of goods sold, % of product sales 25.4% → 28.0% Mainly a higher blended royalty rate paid to Sanofi as Amvuttra sales grow Worse
Early clinical-data updates ALN-6400 and ALN-2232 data expected in 2H 2026 2H 2026 → with Q4 results in February 2027 Watch

Sources: the company’s Q2 and Q3 releases and 10-Qs. The percentage increases are our calculations from reported figures.

What got better

Sales and guidance

Total product sales were $1.29 billion, up 52% from a year earlier. Amvuttra’s US sales rose 12% from Q2. Amvuttra sales outside the US rose about 9%. Alnylam attributed international TTR growth to heart-disease launches and partner-order timing. Royalty revenue, mostly from Novartis’s cholesterol drug Leqvio, rose to $94.7 million from $71.7 million in Q2. Alnylam reiterated its July ranges, but CFO Jeff Poulton said on the Oct 29 earnings call that it expected TTR sales at the low end of the $4.2–4.5 billion range.

Heart-trial evidence

At the European Society of Cardiology meeting, Alnylam presented a prespecified subgroup analysis (an analysis of groups within the trial planned in advance) of HELIOS-B, the trial behind Amvuttra’s heart approval. Alnylam reported consistent treatment effects on deaths and recurrent cardiovascular events in patients with and without tafamidis at the start, but said the trial was not large enough to establish benefit specifically in patients already taking tafamidis. Tafamidis is Pfizer’s stabilizer pill, which helps keep the TTR protein from misfolding. AstraZeneca and Ionis said in July that their rival drug Wainua, which also reduces production of TTR, missed its main goal in a trial where most participants were already taking stabilizers. That was a separate trial, not a direct comparison with Amvuttra.

What needs watching

The pace of demand

US TTR sales rose $99 million from Q2. Alnylam attributed $81 million to higher demand, $17 million to inventory, and the rest to a modest net-price increase that included about $10 million of favourable gross-to-net adjustments, which are changes in estimated rebates and discounts. To reach the middle of its TTR range, Alnylam would need about $1.26 billion of fourth-quarter TTR sales, roughly $110 million more than Q3; the low end of $4.2 billion needs about $1.11 billion, below Q3’s $1.15 billion (our calculation).

Costs and profit

Cost of goods sold rose to 28% of product sales. Alnylam attributed this mainly to Amvuttra’s growth and the higher average royalty rate it pays Sanofi. Alnylam reported operating income of $346 million, down about 6% from a year earlier. The comparison includes a $300 million Roche milestone recorded in Q3 2025. Net income of $2.17 billion includes a $1.9 billion tax benefit from recognising previously reserved US tax benefits that Alnylam now expects to use. This lifts reported profit but not cash. Cash, cash equivalents and marketable securities rose to $3.6 billion.

Pipeline timing and a generic challenge

Patient data for ALN-6400 in hereditary hemorrhagic telangiectasia, an inherited bleeding disorder, and for the obesity drug ALN-2232 moved from the second half of 2026 to February 2027. Alnylam is expanding TRITON-CM, the heart trial of its next-generation drug nucresiran, for the second time this year, to about 2,250 patients; the company says the expansion is enriched for patients with early disease and ensures adequate study power under conservative event-rate estimates. It still expects a heart-disease launch by 2030, assuming positive data and regulatory approval. The 10-Q and court records show that Alnylam sued Cipla on Sep 16, 2026 over its proposed generic Amvuttra. The suit does not establish FDA approval or a launch date.

Does this change the long-term story?

Our read: not its direction, but the pace again came in slower. The July reset still stands. Alnylam’s reported dollar contribution from higher US TTR demand was smaller than in Q2. These figures do not establish whether new-patient growth slowed. The patent suit against Cipla and the timing of nucresiran, which Alnylam says would carry no royalty to Sanofi, are the longer-run items to follow.

For the full record of filings, dilution and cash, see Alnylam Pharmaceuticals: The Long View.

What to watch next

Nov 2026
FDA target action date for Regeneron's cemdisiran in generalized myasthenia gravis. If approved, Alnylam is eligible for tiered royalties of up to 15% on global net sales.
Nov 6–9, 2026
Two-year follow-up results from the HELIOS-B extension, in which participants know their treatment, at the American Heart Association meeting.
Nov 15–18, 2026
A comparison of Amvuttra with BridgeBio's acoramidis using results from separate trials, at the International Symposium of Amyloidosis.
Dec 12–15, 2026
Healthy-volunteer data for ALN-6400, an experimental bleeding-disorder drug, at the American Society of Hematology meeting.
Feb 2027
Q4 results, with ALN-6400 Phase 2 data in hereditary hemorrhagic telangiectasia and ALN-2232 Phase 1 obesity data.

Quick questions

Did Alnylam change its 2026 guidance?

No. On Oct 29, 2026 it reiterated every line, including $4.2–4.5 billion of TTR sales, $4.7–5.1 billion of total product sales and $575–625 million of collaboration and royalty revenue. Its CFO said on the call that TTR sales were expected at the low end of the $4.2–4.5 billion range.

Why was Alnylam's Q3 net income $2.17 billion?

It includes a $1.9 billion income-tax benefit from recognising previously reserved US tax benefits that Alnylam now expects to use against future taxable income. That is an accounting gain, not cash.

How much additional US TTR revenue did Alnylam attribute to higher demand in Q3?

Alnylam said US TTR sales rose $99 million from Q2: $81 million from higher demand, a $17 million inventory benefit, and a modest increase in net price that included about $10 million of favourable adjustments.

Updates

  • : Corrected Nov 3: the UBS and Jefferies target changes are now attributed to ad-hoc-news and Investing.com (Oct 16) instead of "press reports"; the UBS change is dated Oct 15, as that report gives it (was Oct 14). Also: the CFO's expectation of TTR sales at the low end of the range is added wherever the reiterated guidance appears; the $173.90 Stock Analysis figure is removed (the Nasdaq close is $174.00); the snapshot notes now give the $1.95B valuation-allowance release and name Blackstone only. Figures otherwise unchanged.

About Alnylam: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.